Policy

As prescription drug affordability boards move toward upper payment limit implementation, uncertainties introduced across the health care system and risks to patient access warrant urgent attention.

Ebola cases hit 1708 as unpaid health workers strike, further straining an outbreak response the World Health Organization says is outpacing containment.

A proposed 2027 CMS rule would cut 340B Drug Pricing Program payments to curb Medicare drug costs and shift savings to patients.

In a cross-sectional study of US hospitals, patient financial assistance and billing policy documents averaged 10th-grade readability scores, with variation significantly associated with several attributes.

Slated to run through December 31, 2027, the Medicare GLP-1 Bridge was originally supposed to run for only 6 months.

The FDA advisory committee supports Moderna’s mRNA-1010 flu vaccine for adults 50-plus, with an August 5 PDUFA decision pending for mFlusiva.

Roughly one-fifth of supplemental indications were approved many years after a drug’s initial launch, many of which target populations with high unmet medical needs.

The authors used Medicaid claims data to quantify program spending, use of services, and enrollment patterns among Medicaid beneficiaries newly diagnosed with a metastatic vs a nonmetastatic cancer.

Vaccine news shaping the 2026-2027 immunization season includes major acquisitions, a key FDA panel vote, and new data on influenza vaccine effectiveness.

House lawmakers reviewed veterans' health bills focused on mental health, rural access, spinal injury care, and military aviation research.

The House passed HR 5347 to extend flexible Medicare ACO quality reporting and support smaller practices transitioning to digital measures.

Senate Democrats introduced a bill to cap out-of-pocket costs at $5000 for traditional Medicare beneficiaries and expand low-income assistance.

National HIV Testing Day highlights how state policies, pharmacists, and long-acting therapies are reshaping access to HIV testing, PrEP, and PEP.

Deloitte's Pete Lyons explains the confidence gap, diverging biopharmaceutical and medical technology risks, and what separates real AI value from activity.

Spending on health expenditures will make up 20.6% of gross domestic product, according to a federal report.

Deloitte's midyear analysis shows internal confidence rising even as external uncertainty over policy, tariffs, and reimbursement persists for biopharma and medtech.

The move follows the close of a 42-day quarantine for American cruise-ship passengers exposed to the rare Andes strain.

The 2 risks operate independently so that social interventions can reduce disease risk regardless of a patient’s genetic profile.

More short-term injections were needed to maintain visual outcomes in patients who lost their co-payment assistance.

A new study finds Texas's abortion ban raised the likelihood of poor maternal mental health by 2.5 points—and 7 points for mothers on Medicaid.

David Brueggeman, MBA, breaks down the underpriced financial risks, redetermination lessons, and what accountable AI actually requires from health plans.

Commercial health care costs are projected to grow 9% in 2027, driven by AI billing tools, pharmacy spend, and provider consolidation, per a PwC report.

A CMS proposed rule would make the Medicare Drug Price Negotiation Program permanent, covering up to 20 drugs per year starting in 2029.

As drug research globalizes, regulators and trial designers must collaborate across regions to bring new treatments to patients.

ACA cancellations rise; HBV re-engagement varies by outreach; rural US has 44% fewer clinicians; diabetes and alopecia need custom care.